Industry News

Biotechnology Industry News

Sanofi is bestowing $625 million…

September 23rd, 2025|FierceBiotech|

Sanofi is bestowing $625 million on its investment arm Sanofi Ventures, seeking to take advantage of a biotech landscape that is light on capital yet still heavy on scientific innovation.

Rome Therapeutics is on the ropes,…

September 23rd, 2025|FierceBiotech|

Rome Therapeutics is on the ropes, with the Boston-based preclinical biotech planning layoffs for the end of the month, evaluating strategic options for its assets and ditching its physical headquarters to go entirely virtual, a

Seres Therapeutics is laying off a…

September 23rd, 2025|FierceBiotech|

Seres Therapeutics is laying off a quarter of its workforce as the microbiome biopharma conserves resources to take its bloodstream infection preventive treatment into phase 2.

Bristol Myers Squibb has ended its…

September 23rd, 2025|FierceBiotech|

Bristol Myers Squibb has ended its R&D losing streak with a hit on one of the dual primary endpoints in a phase 3 multiple myeloma trial. But, with the study continuing to evaluate the other

Roche’s head of metabolic…

September 23rd, 2025|FierceBiotech|

Roche’s head of metabolic product development said the company is firing “on full cylinders” to get a phase 3 trial of its GLP-1/GIP drug launched next year.

Merck & Co. has doubled down…

September 23rd, 2025|FierceBiotech|

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets.

MapLight Therapeutics has…

September 22nd, 2025|FierceBiotech|

MapLight Therapeutics has illuminated a path toward an initial public offering, filing with the Securities and Exchange Commission to be listed on the Nasdaq under the ticker symbol "MPLT."

Ionis Pharmaceuticals is eyeing a…

September 22nd, 2025|FierceBiotech|

Ionis Pharmaceuticals is eyeing a new rare disease approval after its antisense oligonucleotide zilganersen successfully improved mobility in patients with the neurological condition Alexander disease.

Pfizer has thrown money at its…

September 22nd, 2025|FierceBiotech|

Pfizer has thrown money at its obesity R&D problem. Having seen its internal assets flounder, the Big Pharma has struck a deal to buy Metsera for an initial $4.9 billion to secure a pipeline of

Roche has set its sights on…

September 22nd, 2025|FierceBiotech|

Roche has set its sights on becoming a “top three” obesity company, according to the pharma’s long-awaited strategy for cracking the weight loss market.

Roche has reported a phase 3 win…

September 22nd, 2025|FierceBiotech|

Roche has reported a phase 3 win for its oral selective estrogen receptor degrader, bouncing back from an earlier setback to deliver data that could support filings for approval in breast cancer.

Sanofi’s long and winding path…

September 22nd, 2025|FierceBiotech|

Sanofi’s long and winding path to get its investigational multiple sclerosis drug over the regulatory finish line has taken another turn with the FDA's move to delay its approval decision on the candidate by three

It’s been less than two years…

September 19th, 2025|FierceBiotech|

It’s been less than two years since Roche dove into the obesity space with its $2.7 billion acquisition of Carmot Therapeutics—but a lot has changed since then.

The German drug developer has…

September 18th, 2025|FierceBiotech|

The German drug developer has tapped four industry leaders to take up spots in its C-suite, a move that has prompted three other executives to leave the company.

Renowned biotech veteran Robert…

September 18th, 2025|FierceBiotech|

Renowned biotech veteran Robert Langer is the executive chair of T.Rx Capital, a VC co-founded by his son Michael Langer and aiming to back "visionary founders" at the intersection of technology and biology.